The microscopic anatomy of experimental rat CC531 colon tumour metastases: Consequences for immunotherapy?

被引:37
作者
Hagenaars, M
Ensink, NG
Basse, PH
Hokland, M
Nannmark, U
Eggermont, AMM
van de Velde, CJH
Fleuren, GJ
Kuppen, PJK
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands
[3] Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA
[4] Aarhus Univ, Dept Med Microbiol & Immunol, Aarhus, Denmark
[5] Univ Gothenburg, Dept Anat & Cell Biol, Gothenburg, Sweden
[6] Univ Rotterdam Hosp, Daniel den Hoed Canc Ctr, Dept Surg, Rotterdam, Netherlands
关键词
colon cancer; immunotherapy; matrix proteins; metastasis; rat;
D O I
10.1023/A:1006774602360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The colon adenocarcinoma cell line CC531 was adopted as a model for immunotherapeutical treatment of experimental colorectal metastases in a syngeneic rat model. We studied the presence and localization of T and natural killer cells, vessels and matrix proteins in in vivo growing CC531 tumours by immunohistochemistry. CC531 tumours were induced either in the lungs by injecting CC531 tumour cells into a tail vein or in the liver by injection of CC531 tumour cells under the liver capsule or into a mesenteric vein. All 3 tumour types were composed of islets of tightly apposed tumour cells surrounded by abundantly present tumour-stroma which contained tumour vessels and matrix proteins. Some of these matrix proteins, especially laminin and collagen IV formed a basal membrane-like structure around the tumour nodules. This structure was most pronounced in mesenteric vein-induced liver tumours and less prominent in subcapsular-induced liver tumours and tail vein-induced lung tumours. Tumour-infiltrating lymphocytes of both T and natural killer cell origin were found in the tumours, but predominantly in the tumour stroma, separated from the islets of tumour cells by the basal membrane-like structure. We hypothesize that the matrix proteins of these tumours play an ambivalent role: they may provide a substratum for migration of effector cells into the tumour stroma but may also provide a barrier preventing direct contact between tumour target cells and immune effector cells.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 39 条
[1]   ACCUMULATION OF ADOPTIVELY TRANSFERRED ADHERENT, LYMPHOKINE-ACTIVATED KILLER-CELLS IN MURINE METASTASES [J].
BASSE, P ;
HERBERMAN, RB ;
NANNMARK, U ;
JOHANSSON, BR ;
HOKLAND, M ;
WASSERMAN, K ;
GOLDFARB, RH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (02) :479-488
[2]  
BASSE PH, 1992, NAT IMMUN, V11, P193
[3]   T-CELL RETARGETING USING BISPECIFIC MONOCLONAL-ANTIBODIES IN A RAT COLON-CARCINOMA MODEL .1. SIGNIFICANT BISPECIFIC LYSIS OF SYNGENEIC COLON-CARCINOMA CC531 IS CRITICALLY DEPENDENT ON PROLONGED PREACTIVATION OF EFFECTOR LYMPHOCYTES-T BY IMMOBILIZED ANTI-T-CELL RECEPTOR ANTIBODY [J].
BEUN, GDM ;
VANEENDENBURG, JDH ;
CORVER, WE ;
VANDEVELDE, CJH ;
FLEUREN, GJ .
JOURNAL OF IMMUNOTHERAPY, 1992, 11 (04) :238-248
[4]   T-CELL RETARGETING USING BISPECIFIC MONOCLONAL-ANTIBODIES IN A RAT COLON-CARCINOMA MODEL .4. TUMOR NEUTRALIZATION IN WINN TYPE ASSAYS [J].
BEUN, GDM ;
VANDEVELDE, CJH ;
FLEUREN, GJ ;
EGGERMONT, AMM .
JOURNAL OF IMMUNOTHERAPY, 1993, 14 (01) :11-15
[5]   MONOCLONAL-ANTIBODY TO A TRIGGERING STRUCTURE EXPRESSED ON RAT NATURAL-KILLER CELLS AND ADHERENT LYMPHOKINE-ACTIVATED KILLER CELLS [J].
CHAMBERS, WH ;
VUJANOVIC, NL ;
DELEO, AB ;
OLSZOWY, MW ;
HERBERMAN, RB ;
HISERODT, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (04) :1373-1389
[6]  
Chaux P, 1996, LAB INVEST, V74, P975
[7]  
CLAASEN HHV, 1992, LAB INVEST, V67, P166
[8]   DISTRIBUTION OF HISTOCOMPATIBILITY AND LEUKOCYTE DIFFERENTIATION ANTIGENS IN NORMAL HUMAN-COLON AND IN BENIGN AND MALIGNANT COLONIC NEOPLASMS [J].
CSIBA, A ;
WHITWELL, HL ;
MOORE, M .
BRITISH JOURNAL OF CANCER, 1984, 50 (05) :699-709
[9]  
DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459
[10]   LAMININ AND FIBRONECTIN IN RECTAL ADENOCARCINOMA - RELATIONSHIP TO TUMOR GRADE, STAGE AND METASTASIS [J].
FORSTER, SJ ;
TALBOT, IC ;
CRITCHLEY, DR .
BRITISH JOURNAL OF CANCER, 1984, 50 (01) :51-61